Home/Resoundant/Rashid Fehmi, CPA
RF

Rashid Fehmi, CPA

Chief Financial Officer

Resoundant

Therapeutic Areas

Resoundant Pipeline

DrugIndicationPhase
Liver MRE for Fibrosis StagingLiver Fibrosis (MASLD, MASH, Hepatitis)Approved
MRE as a Biomarker in Clinical TrialsMASH (as a surrogate endpoint)Biomarker Qualification
MRE for Tumor CharacterizationOncology (Brain, Breast, Prostate Tumors)Pre-clinical/Research